علاج الصلابة الجلدية الموضعية مع إصابة جلدية شديدة وإصابة عضلية هيكلية

References

DOI: 10.1111/ddg.15328

• In subtypes with severe skin or musculoskeletal involvement, systemic therapy with methotrexate is recommended.
• We recommend methotrexate (MTX) (off-label) as the first-line systemic therapy for LoS with severe skin and/or musculoskeletal involvement.
• Arthritis, myositis, osteitis, or depending on the severity, musculoskeletal pain symptoms attributable to LoS.
• We recommend a treatment duration of at least 12 months with methotrexate after achieving remission.
• After achieving therapeutic success, a dose reduction may be considered.
• We suggest considering systemic glucocorticosteroid therapy in addition to the systemic treatment with MTX during the active phase of LoS.
• When assessing the effectiveness of the chosen therapeutic concept, it should be noted that the reduction of sclerosis typically takes at least 8 to 12 weeks in most cases.